Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis

Hum Vaccin Immunother. 2022 Dec 31;18(1):2027714. doi: 10.1080/21645515.2022.2027714. Epub 2022 Feb 22.

Abstract

This study comprehensively evaluated and compared three human rabies vaccines. Seven electronic databases were systematically searched. The Cochrane Handbook v5.1.0 was used to assess the risk of bias. A random-effects model was used to combine individual rates, and network meta-analysis was used for pairwise comparisons. Twenty-seven articles were included, with a total of 18,630 participants. The pooled incidence of the total adverse reaction to HDCV was significantly lower than that of PCECV. HDCV administration resulted in a lower incidence of local pain, fever, and weakness than purified Vero cell vaccine. HDCV caused a lower incidence of local pain and fever than PCECV. No significant difference was observed in terms of the seroconversion rate on day 7 or the rabies virus-neutralizing antibody titer on day 14. HDCV demonstrated superiority in terms of safety compared with the other two rabies vaccines, while the same was not observed in terms of immunogenicity.

Keywords: Rabies vaccines; adverse reaction; immunogenicity; meta-analysis; post-exposure prophylaxis.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral
  • Chick Embryo
  • Chickens
  • Chlorocebus aethiops
  • Diploidy
  • Fever / chemically induced
  • Humans
  • Pain / chemically induced
  • Post-Exposure Prophylaxis
  • Rabies Vaccines*
  • Rabies virus*
  • Rabies* / prevention & control
  • Vero Cells

Substances

  • Antibodies, Viral
  • Rabies Vaccines

Grants and funding

This study was funded by the Natural Science Foundation of Jiangsu Province [grant number: BK20190357].